転移性去勢抵抗性前立腺がん患者の前立腺特異的膜抗原を標的とする、ドセタキセルをナノ粒子に封入したBIND-014の有効性と安全性;第Ⅱ相試験【JAMA Oncol】

JAMA Oncol. 2018年7月5日オンライン版

Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2 Clinical Trial

Key Points

Questions What is the safety and efficacy of BIND-014, a docetaxel-containing nanoparticle targeting prostate-specific membrane antigen (PSMA), in metastatic castration-resistant prostate cancer, and does PSMA expression on circulating tumor cells decrease with treatment?

Findings In this phase 2 clinical trial of 42 chemotherapy-naive patients receiving BIND-014 therapy for metastatic castration-resistant prostate cancer, the median radiographic progression-free survival was 9.9 months. The most common adverse events were fatigue. nausea, and diarrhea.

Meaning Tumor cell death was associated with PSMA expression on circulating tumor cells, which, if validated, could serve as a pharmacodynamic response measure and help select patients with metastatic castration-resistant prostate cancer who are most likely to benefit from PSMA-directed treatment.

 

 

 

コメント

Leave a comment

Your email address will not be published.


*